Dermatology Unit, Department of Surgical, Medical, Dental & Morphological Sciences with Interest Transplant, Oncological & Regenerative Medicine, University of Modena & Reggio Emilia, Modena, Italy.
Allergology Unit, Department of Surgical, Medical, Dental & Morphological Sciences with Interest Transplant, Oncological & Regenerative Medicine, University of Modena & Reggio Emilia, Modena, Italy.
Skin Res Technol. 2020 Nov;26(6):779-787. doi: 10.1111/srt.12868. Epub 2020 Mar 24.
Atopic dermatitis (AD) is a chronic inflammatory disease. Recently, dupilumab was approved for moderate-to-severe AD. D-OCT is a noninvasive tool for the characterization of skin diseases.
To describe the changes observed with D-OCT in lesional and clinically healthy skin of patients with refractory severe AD under dupilumab treatment.
We analyzed AD lesions and healthy skin by D-OCT. Clinical scores of AD severity were assessed at baseline (T0) and after 1 and 3 months of treatment (T1, T2). Descriptive statistics, chi-square test, and t test were used to compare the analyzed parameters over time and between AD lesions and clinically healthy skin.
At baseline, average EASI was 45.7. During the follow-up, EASI75 and EASI90 were achieved in 57% and 36% of patients at T1 and 100% and 86% of patients at T2, respectively. Lesional skin D-OCT parameters related to epidermal remodeling and inflammation evidenced a significant improvement after 1 month of treatment. In clinically healthy skin, D-OCT parameters improved significantly after 3 months of treatment, especially for collagen remodeling and inflammation.
The study demonstrates that the clinical improvement of severe AD patients under dupilumab treatment is correlated with specific D-OCT changes of patients' lesional and clinically healthy skin.
特应性皮炎（AD）是一种慢性炎症性疾病。最近，度普利尤单抗被批准用于治疗中重度 AD。D-OCT 是一种用于皮肤疾病特征描述的非侵入性工具。
描述接受度普利尤单抗治疗的难治性重度 AD 患者的皮损和临床健康皮肤在 D-OCT 下的变化。
我们通过 D-OCT 分析 AD 皮损和健康皮肤。在基线（T0）和治疗 1 个月（T1）和 3 个月（T2）时评估 AD 严重程度的临床评分。使用描述性统计、卡方检验和 t 检验比较随时间的分析参数以及 AD 皮损和临床健康皮肤之间的差异。
基线时，EASI 平均为 45.7。在随访期间，T1 时 57%的患者达到了 EASI75 和 EASI90，T2 时 100%和 86%的患者达到了 EASI75 和 EASI90。治疗 1 个月后，与表皮重塑和炎症相关的皮损皮肤 D-OCT 参数显著改善。治疗 3 个月后，临床健康皮肤的 D-OCT 参数显著改善，尤其是胶原重塑和炎症。
研究表明，接受度普利尤单抗治疗的重度 AD 患者的临床改善与患者皮损和临床健康皮肤的特定 D-OCT 变化相关。
